Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RELIEF THERAPEUTICS Holding ( (CH:RLF) ) has provided an announcement.
Relief Therapeutics has announced a proposed business combination with NeuroX, which recently acquired MindMaze, a leader in digital neurotherapeutics. This merger aims to create a publicly listed, AI-driven health tech company that integrates digital and pharmacological treatments for neurological diseases. The transaction is expected to close in Q4 2025, subject to customary conditions and approvals, and is anticipated to significantly enhance Relief’s market presence and growth potential.
More about RELIEF THERAPEUTICS Holding
Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company based in Geneva, focused on developing innovative treatments for rare and debilitating diseases. The company specializes in drug delivery systems and drug repurposing, with a clinical pipeline targeting rare dermatological, metabolic, and respiratory conditions. Relief has successfully brought several products to market through licensing and distribution partnerships and is listed on the SIX Swiss Exchange.
Average Trading Volume: 37,364
Technical Sentiment Signal: Sell
Current Market Cap: CHF29.11M
Learn more about RLF stock on TipRanks’ Stock Analysis page.